2024-09-11 - Analysis Report
## AMGN Stock Analysis

**Company Overview:** Amgen is a leading biotechnology company that develops, manufactures, and markets innovative therapies for serious illnesses.

**Performance Analysis:**

1. **Performance vs. S&P 500 (VOO):** 
    - AMGN's cumulative return over the period is 54.48%, lagging behind the S&P 500's 83.37%.
    - The relative divergence, at -28.89, indicates that AMGN's performance is currently 48.69% lower than the S&P 500's performance over the considered time frame. This means that AMGN has underperformed the S&P 500 by nearly half.

2. **Recent Price Movements:**
    - Closing price: $325.92
    - 5-day moving average: $326.4
    - 20-day moving average: $326.6
    - 60-day moving average: $323.28

    - AMGN's price has been trading slightly below its 5-day, 20-day and 60-day moving averages, indicating a potential downward trend.

3. **Technical Indicators:**
    - **RSI:** 47.3
        - The RSI suggests that AMGN is currently in neutral territory, neither overbought nor oversold.
    - **PPO:** -0.18
        - The negative PPO value indicates a bearish trend.
    - **Delta_Previous_Relative_Divergence:** -3.28
        - The negative value indicates a recent short-term decline in relative divergence.
    - **Expected Return:** 7.18%
        - This is the estimated maximum return over the next 5 years, based on current investment amounts.

4. **Recent Earnings and Outlook:**

    | Date       | EPS      | Revenue       |
    |------------|----------|---------------|
    | 2024-08-07 | 1.39     | $8.39 B        |
    | 2024-05-03 | -0.21    | $7.45 B        |
    | 2023-10-31 | 3.23     | $6.90 B        |
    | 2023-08-04 | 2.58     | $6.99 B        |
    | 2024-08-07 | 2.58     | $6.99 B        |

    - The most recent earnings report for Q2 2024 showed an EPS of $1.39, exceeding analysts' estimates. This indicates a strong performance in the recent quarter. 
    - Revenue also grew significantly to $8.39B, further solidifying AMGN's strong performance.

**Overall Analysis:**

- AMGN has underperformed the S&P 500 (VOO) over the considered period, despite showing strong recent earnings results.
- Technical indicators suggest a potential downward trend.
- The company's current stock price is trading below its recent moving averages.
- The expected return remains relatively positive, but needs further analysis considering the recent performance.

**Conclusion:**

Although AMGN's recent earnings demonstrate strong performance, its underperformance against the S&P 500 and technical indicators signaling a potential downward trend raise concerns. While the expected return remains positive, further analysis is needed to determine if this performance will continue in the future. Investors should consider these factors before making any investment decisions. 
